Pulsehaler™ and COVID-19

Breathe Well,             Live Well

COVID Alert.jpg

CHRONIC OBSTRUCTIVE

  PULMONARY DISEASE (COPD)

Chronic Obstructive Pulmonary Disease (COPD) affects 5-14% of the world population over 40 years of age. Our mission is to reverse the suffering of COPD patients, and provide them with renewed quality of life and hope for the future.

Over 384M Patients
Direct Healthcare Costs of $30B in the USA and €50B in Europe
3rd Leading Cause of Death
Pulsehaler is a novel treatment that uses Dynamic Air Pressure Pulses to re-open closed airways,improve exercise capacity and Quality of Life in COPD patients. 

NOTE: Pulsehaler is not yet cleared or approved for sale by any regulatory authority.

LEADERSHIP

Cliff Ansel, CEO

Medical Device Executive and Entrepreneur

Yuval Avni, CTO

Serial Entrepreneur, Inventor and Product Developer

Need more details? Contact us

We are here to assist. Contact us by phone, email or via our social media channels.

ISO13485_edited_edited.png

Click for Certificate

  • LinkedIn

Co-funded by the Horizon 2020 programme of the European Union

Copyright © 2020 Respinova Ltd. All rights reserved.